Petri Huhtinen Finland

<
Petri Huhtinen, PhD, Optomed’s Clinical Director manages company’s clinical study portfolio ensuring that clinical view is in the core of company’s strategy. Furthermore, he works closely with Optomed’s AI-partners who are using retinal images to develop AI algorithms for various disorders. Dr Huhtinen has been involved in numerous screening projects and programs for more than 15 years. The focus of the programs has varied between eye disease, cancer and various congenital disease. Geographical distribution has been wide, ranging from South-East Asia to Americas, and from Sub-Saharan Africa to the Nordic Counties. During the years with screening Huhtinen has become a big fan of preventive healthcare where successful and cost-efficient screening plays a key role. Dr Huhtinen holds PhD in in vitro diagnostics, MSc in biochemistry and BBA in information systems science.

Day 1 - 17 October 2022

Time Session
14:00
16:00
R&D and MedTech Innovation of Nordic Companies
The R&D to commercialisation route for digital health solutions are very challenging. How do aspiring Nordic innovators and researchers minimise risks to ensure higher chances of commercial success? A Case-Sharing session by the Nordic Companies on their journey to success